Tag: Shilpa Medicare
Shilpa Medicare gets Import Alert from USFDA
Shilpa Medicare has received an import alert 66-40 on February 17, 2021, pursuant to the USFDA inspection of the Unit IV, Jadcherla,...
USFDA issues warning to Shilpa Medicare for cGMP violations
NEW DELHI: The US Food and Drug Administration (USFDA) has issued a warning letter to Shilpa Medicare for violating current good manufacturing practice norms...
USFDA issues warning letter to Shilpa Medicare, Telangana
Shilpa Medicare has received a warning letter through email from the USFDA for its Jadcherla facility, Telangana.
The company...
Shilpa Medicare IBRUSHIL for treatment of leukaemia
Shilpa Medicare announced the launch of the Indian branded generic of lbrutinib, an anti-cancer drug under the brand name IBRUSHIL. Earlier it...
Shilpa Medicare gets EIR from USFDA
Shilpa Medicare Limited (SML) has announced the receipt of Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for...
Shilpa Medicare gets 15 observations from USFDA
Shilpa Medicare has received 15 observations from US Food and Drug Administration (FDA) for the company's finished dosage formulation facility (sterile...